Sabby Capital

Sabby Capital is an investment advisory firm founded in 2018 and based in New Jersey. The firm specializes in the healthcare sector and employs quantitative fundamental strategies alongside event-driven relative value arbitrage. With a focus on asset volatility, Sabby Capital aims to identify profitable investment opportunities within the healthcare industry, leveraging its analytical approach to manage risk and enhance returns.

Hal Mintz

Founder

13 past transactions

RooLife Group

Post in 2022
RooLife Group is a platform that connects lifestyle brands and producers with consumers, focusing on market entry and cross-border e-commerce. The company offers consultancy services to help businesses navigate new markets and enhance their online sales through fully integrated digital marketing strategies. Utilizing advanced artificial intelligence and machine learning, RooLife Group delivers personalized marketing solutions that target individual consumers in real-time. The company's primary focus is on driving sales through e-commerce marketplaces, specifically facilitating transactions for international brands targeting Chinese consumers. This includes enabling payment options through popular platforms like WeChat and Alipay, positioning RooLife Group as a key player in the digital marketing and customer acquisition landscape.

Epic Sciences

Series D in 2017
Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through innovative testing methods. The company specializes in developing highly sensitive tests to identify and characterize circulating tumor cells (CTCs) from minimally invasive blood samples. Its advanced platform can profile single-cell phenotypes and genotypes, assessing various characteristics such as biomarker expression levels and morphologic traits. Epic Sciences also offers the Oncotype DX AR-V7 Nucleus Detect test for patients with metastatic castration-resistant prostate cancer, along with biopharmaceutical solutions. The company collaborates with biotechnology and pharmaceutical partners, major cancer centers, and research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and provide real-time biopsy material for cancer treatment guidance. Founded in 2008, Epic Sciences is committed to facilitating quick and effective cancer diagnostics.

Ardelyx

Post in 2015
Ardelyx, Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative oral therapeutics for cardiorenal diseases. Founded in 2007 and headquartered in Fremont, California, the company focuses on addressing significant unmet medical needs through first-in-class medicines. Its lead product candidate, tenapanor, has completed Phase 3 clinical trials for treating irritable bowel syndrome with constipation and hyperphosphatemia in end-stage renal disease patients on dialysis. Additionally, Ardelyx is advancing RDX013, a small molecule potassium secretagogue targeting hyperkalemia, and has other candidates in its pipeline, including RDX002 and RDX009, which are in preclinical development for chronic kidney disease and type 2 diabetes, respectively. Ardelyx employs a proprietary drug discovery platform aimed at creating non-systemic products that target specific transporters and receptors to minimize side effects associated with systemic exposure.

Champions Oncology

Post in 2015
Champions Oncology, Inc. develops and sells technology solutions and products aimed at personalizing oncology drug development and treatment. Central to its offerings is the Tumorgraft Technology Platform, which involves implanting human tumors in immune-deficient mice to derive personalized treatment options based on tumor-specific data. The company provides Personalized Oncology Solutions (POS) to assist physicians in tailoring cancer therapies through drug panels and related services, as well as Translational Oncology Solutions (TOS) that help pharmaceutical and biotechnology firms in their drug development processes. Champions Oncology's products, including TumorGraft implants and drug panels, are marketed to patients and healthcare providers through various channels. Founded by leading experts in oncology, the company was established in 1985 and is headquartered in Hackensack, New Jersey.

Cidara Therapeutics

Series B in 2015
Cidara Therapeutics is a biotechnology company based in San Diego, California, established in 2012. The company specializes in the discovery and development of innovative anti-infective therapies for serious diseases, particularly those that affect individuals with compromised immune systems. Its lead candidate, rezafungin acetate, is an antifungal agent designed to treat and prevent severe invasive fungal infections, such as candidemia and invasive candidiasis, which carry significant mortality risks. In addition to its antifungal efforts, Cidara is advancing its proprietary Cloudbreak platform, which focuses on developing antiviral Fc-conjugates aimed at preventing and treating various viral infections, including influenza, RSV, HIV, and coronavirus. Cidara's mission is to transform treatment and prevention strategies for life-threatening illnesses.

Global Blood Therapeutics

Series B in 2015
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, specializing in the discovery, development, and delivery of innovative treatments for underserved patient populations. The company's lead product candidate is Oxbryta (voxelotor), an oral, once-daily therapy designed to treat sickle cell disease (SCD). Oxbryta has successfully completed Phase III clinical trials for adult and adolescent patients and is currently being evaluated in a Phase IIa trial for younger patients. Additionally, Global Blood Therapeutics has a collaboration agreement with Syros Pharmaceuticals to develop therapies targeting both SCD and beta thalassemia. Founded in 2011, the company is also engaged in research for other blood-based disorders, including hereditary angioedema.

Naurex

Series C in 2014
Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The firm is pioneering a new mechanism for modulating the N-methyl-D-aspartic acid receptor (NMDAR), which distinguishes its approach from existing treatments. Researchers at Naurex have developed a new class of drugs known as glycine-site functional partial agonists (GFPAs), designed to safely modulate the NMDAR. The company's drug development pipeline includes its first-generation molecule, GLYX-13, and a second-generation series, NRX-1050, along with additional compounds derived from its platform of novel NMDAR modulators. Naurex aims to address significant unmet needs in psychiatry and neurology through these advancements.

Blueprint Medicines

Series C in 2014
Blueprint Medicines Corporation is a biopharmaceutical company that specializes in developing small molecule kinase inhibitors aimed at treating genomically defined cancers and rare diseases. Founded in 2008 and headquartered in Cambridge, Massachusetts, the company focuses on personalized cancer therapies by leveraging its proprietary chemical library and advanced research capabilities. Its key drug candidates include avapritinib for systemic mastocytosis and gastrointestinal stromal tumors, and pralsetinib for RET-altered non-small cell lung cancer and medullary thyroid carcinoma. Additionally, Blueprint Medicines is advancing BLU-263, a KIT inhibitor for mast cell disorders, and fisogatinib for advanced hepatocellular carcinoma, both currently in clinical trials. The company’s innovative approach seeks to address the molecular drivers of cancer and resistance mechanisms, aiming to enhance treatment effectiveness and patient outcomes. Blueprint Medicines has established collaborations with several pharmaceutical companies to further its research and development efforts.

Bellicum Pharmaceuticals

Series C in 2014
Bellicum Pharmaceuticals is a clinical-stage biopharmaceutical company based in Houston, Texas, focused on developing innovative cellular immunotherapies for the treatment of hematological cancers and solid tumors. The company is advancing its product candidates, including BPX-601, an autologous GoCAR-T therapy aimed at solid tumors expressing prostate stem cell antigen, and BPX-603, a dual-switch GoCAR-T therapy targeting solid tumors that express human epidermal growth factor receptor 2. Bellicum utilizes its proprietary Chemical Induction of Dimerization technology platform, which allows for real-time control of immune system components to enhance therapeutic efficacy. The company collaborates with various institutions, including Adaptimmune Therapeutics and Baylor College of Medicine, to further its research and development efforts. Founded in 2004, Bellicum Pharmaceuticals continues to make strides in cancer treatment through its novel immunotherapeutic approaches.

Dermira

Series C in 2014
Dermira, Inc. is a biopharmaceutical company based in Menlo Park, California, that focuses on developing and commercializing therapies for dermatologic conditions in the United States. The company offers QBREXZA, a once-daily topical treatment for primary axillary hyperhidrosis in patients aged nine years and older. Additionally, Dermira is advancing several product candidates, including lebrikizumab, a monoclonal antibody currently in Phase IIb trials for moderate-to-severe atopic dermatitis, and glycopyrronium tosylate, which is in Phase III trials for hyperhidrosis. Dermira also has collaborations with other companies for the development and commercialization of its products, such as a partnership with UCB Pharma for Cimzia, aimed at treating chronic plaque psoriasis. Founded in 2010, Dermira aims to provide innovative solutions for dermatologists and their patients.

Adverum Biotechnologies

Series B in 2014
Adverum Biotechnologies is a clinical-stage gene therapy company focused on developing innovative treatments for ocular and rare diseases. Headquartered in Redwood City, California, the company aims to establish gene therapy as a new standard of care, aspiring to provide functional cures that restore vision and prevent blindness. Its pipeline includes several product candidates, notably ADVM-022, which targets wet age-related macular degeneration through a single intravitreal injection designed to deliver long-term therapeutic effects. Other candidates include ADVM-043 for alpha-1 antitrypsin deficiency and ADVM-053 for hereditary angioedema. Adverum collaborates with partners like Editas Medicine and Regeneron Pharmaceuticals to leverage advanced AAV vectors and develop treatments for various inherited retinal diseases and ocular therapeutic targets. Founded in 2006, the company was previously known as Avalanche Biotechnologies and rebranded in 2016.

Stem Cell Therapeutics

Venture Round in 2013
Stem Cell Therapeutics Corp. is a Toronto-based biopharmaceutical company focused on developing innovative cancer therapies derived from cancer stem cell research. As the only public entity in Canada dedicated to this field, the company leverages over 50 years of pioneering research in stem cells, collaborating with prominent academic institutions and oncology treatment centers in Toronto, a renowned hub for cancer research. In addition to its cancer initiatives, the company is also involved in creating drug-based therapies aimed at treating central nervous system diseases. These therapies stimulate a patient's own resident stem cells to facilitate the repair of neurological functions impaired by conditions such as stroke, traumatic brain injury, and multiple sclerosis, aiming to restore health in patients suffering from various neurodegenerative disorders.

Arno Therapeutics

Post in 2013
Arno Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative treatments for cancer and other life-threatening diseases. The company's pipeline features several drug candidates, including Onapristone, a type 1 anti-progestin hormone blocker currently in Phase I/II clinical studies aimed at treating various solid tumors, including breast and endometrial cancers in post-menopausal women, as well as advanced castration-resistant prostate cancer in men. Another candidate, AR-12, has completed Phase I clinical studies for the treatment of solid tumors and hematological malignancies, and is also undergoing pre-clinical studies for various anti-microbial targets. Additionally, AR-42, an orally available therapy, is in Phase I investigator-initiated clinical studies for hematological malignancies and solid tumors. Arno Therapeutics has established license agreements with multiple institutions and a co-development agreement with Leica Biosystems Newcastle Ltd., and is headquartered in Flemington, New Jersey.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.